SGK
IONS icon

Steigerwald Gordon & Koch’s Ionis Pharmaceuticals IONS Stock Holding History

Steigerwald Gordon & Koch’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
265
-30
-10% -$2.26K ﹤0.01% 439
2026
Q1 		$22.2K Sell
295
-85
-22% -$6.71K ﹤0.01% 409
2025
Q4 		$30.1K Hold
380
– – ﹤0.01% 390
2025
Q3 		$24.9K Buy
+380
New +$18.6K ﹤0.01% 397

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Steigerwald Gordon & Koch's IONS Position: Q2 2026 in Review

Steigerwald Gordon & Koch reduced its Ionis Pharmaceuticals (IONS) stake by 10% in Q2 2026, selling an estimated $2.26K and leaving 265 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #439.

Steigerwald Gordon & Koch first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $30.1K in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Steigerwald Gordon & Koch held 265 shares of Ionis Pharmaceuticals worth $21K as of Q2 2026.
  • Steigerwald Gordon & Koch sold 30 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.26K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #439 holding.
  • Steigerwald Gordon & Koch first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Steigerwald Gordon & Koch's Ionis Pharmaceuticals position peaked at $30.1K in Q4 2025.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.